479 related articles for article (PubMed ID: 37582478)
21. Viral burden rebound in hospitalised patients with COVID-19 receiving oral antivirals in Hong Kong: a population-wide retrospective cohort study.
Wong CKH; Lau KTK; Au ICH; Lau EHY; Poon LLM; Hung IFN; Cowling BJ; Leung GM
Lancet Infect Dis; 2023 Jun; 23(6):683-695. PubMed ID: 36796397
[TBL] [Abstract][Full Text] [Related]
22. Real-world Effectiveness of Molnupiravir and Nirmatrelvir/Ritonavir as Treatments for COVID-19 in Patients at High Risk.
Paraskevis D; Gkova M; Mellou K; Gerolymatos G; Psalida N; Gkolfinopoulou K; Kostaki EG; Loukides S; Kotanidou A; Skoutelis A; Thiraios E; Saroglou G; Zografopoulos D; Filippou D; Mossialos E; Zaoutis T; Gaga M; Tsiodras S; Antoniadou A
J Infect Dis; 2023 Dec; 228(12):1667-1674. PubMed ID: 37565522
[TBL] [Abstract][Full Text] [Related]
23. Incidence of Viral Rebound After Treatment With Nirmatrelvir-Ritonavir and Molnupiravir.
Wong GL; Yip TC; Lai MS; Wong VW; Hui DS; Lui GC
JAMA Netw Open; 2022 Dec; 5(12):e2245086. PubMed ID: 36472873
[TBL] [Abstract][Full Text] [Related]
24. Comparison of azvudine, molnupiravir, and nirmatrelvir/ritonavir in adult patients with mild-to-moderate COVID-19: a retrospective cohort study.
Chen MP; Jiang DX; Rang JX; Zhuo HB; Zhou ZG
Sci Rep; 2024 Feb; 14(1):3318. PubMed ID: 38337014
[TBL] [Abstract][Full Text] [Related]
25. Determining and Comparing the Real-World Effectiveness of Molnupiravir and Nirmatrelvir-Ritonavir in Patients Hospitalized With COVID-19.
Jang YR; Oh Y; Kim JY
J Korean Med Sci; 2024 Feb; 39(6):e52. PubMed ID: 38374626
[TBL] [Abstract][Full Text] [Related]
26. Effectiveness of molnupiravir vs nirmatrelvir-ritonavir in non-hospitalised and hospitalised patients with COVID-19: a target trial emulation study.
Wan EYF; Yan VKC; Wong ZCT; Chui CSL; Lai FTT; Li X; Wong CKH; Hung IFN; Lau CS; Wong ICK; Chan EWY
EClinicalMedicine; 2023 Oct; 64():102225. PubMed ID: 37753272
[TBL] [Abstract][Full Text] [Related]
27. Real-Life Comparison of Antivirals for SARS-CoV-2 Omicron Infection in Patients With Hematologic Malignancies.
Aiello TF; Peyrony O; Chumbita M; Monzó P; Lopera C; Puerta-Alcalde P; Magnano L; Fernández-Avilés F; Cuesta G; Tuset M; Mensa J; Esteve J; Marcos MA; Soriano A; Garcia-Vidal C
Influenza Other Respir Viruses; 2024; 18(3):e13264. PubMed ID: 38468434
[TBL] [Abstract][Full Text] [Related]
28. Effectiveness of nirmatrelvir-ritonavir in preventing hospital admissions and deaths in people with COVID-19: a cohort study in a large US health-care system.
Lewnard JA; McLaughlin JM; Malden D; Hong V; Puzniak L; Ackerson BK; Lewin BJ; Kim JS; Shaw SF; Takhar H; Jodar L; Tartof SY
Lancet Infect Dis; 2023 Jul; 23(7):806-815. PubMed ID: 36933565
[TBL] [Abstract][Full Text] [Related]
29. Association of Molnupiravir and Nirmatrelvir-Ritonavir with reduced mortality and sepsis in hospitalized omicron patients: a territory-wide study.
Wai AK; Lee TT; Chan SC; Chan CY; Yip ET; Luk LY; Ho JW; So KW; Tsui OW; Lam ML; Lee SY; Yamamoto T; Tong CK; Wong MS; Wong EL; Rainer TH
Sci Rep; 2023 May; 13(1):7832. PubMed ID: 37188726
[TBL] [Abstract][Full Text] [Related]
30. Comparing molnupiravir and nirmatrelvir/ritonavir efficacy and the effects on SARS-CoV-2 transmission in animal models.
Cox RM; Lieber CM; Wolf JD; Karimi A; Lieberman NAP; Sticher ZM; Roychoudhury P; Andrews MK; Krueger RE; Natchus MG; Painter GR; Kolykhalov AA; Greninger AL; Plemper RK
Nat Commun; 2023 Aug; 14(1):4731. PubMed ID: 37550333
[TBL] [Abstract][Full Text] [Related]
31. Effectiveness and Adverse Events of Nirmatrelvir/Ritonavir Versus Molnupiravir for COVID-19 in Outpatient Setting: Multicenter Prospective Observational Study.
Park JJ; Kim H; Kim YK; Lee SS; Jung E; Lee JS; Lee J
J Korean Med Sci; 2023 Oct; 38(42):e347. PubMed ID: 37904658
[TBL] [Abstract][Full Text] [Related]
32. Real-world use of nirmatrelvir-ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort study.
Aggarwal NR; Molina KC; Beaty LE; Bennett TD; Carlson NE; Mayer DA; Peers JL; Russell S; Wynia MK; Ginde AA
Lancet Infect Dis; 2023 Jun; 23(6):696-705. PubMed ID: 36780912
[TBL] [Abstract][Full Text] [Related]
33. New Perspectives on Antimicrobial Agents: Molnupiravir and Nirmatrelvir/Ritonavir for Treatment of COVID-19.
Atmar RL; Finch N
Antimicrob Agents Chemother; 2022 Aug; 66(8):e0240421. PubMed ID: 35862759
[TBL] [Abstract][Full Text] [Related]
34. Comparing Molnupiravir to Nirmatrelvir/Ritonavir (Paxlovid) in the Treatment of Mild-to-Moderate COVID-19 in Immunocompromised Cancer Patients.
Haddad AJ; Hachem RY; Moussa M; Jiang Y; Dagher HR; Chaftari P; Chaftari AM; Raad II
Cancers (Basel); 2024 Mar; 16(5):. PubMed ID: 38473412
[TBL] [Abstract][Full Text] [Related]
35. Early administration of nirmatrelvir/ritonavir leads to faster negative SARS-CoV-2 nasal swabs than monoclonal antibodies in COVID 19 patients at high-risk for severe disease.
Colaneri M; Scaglione G; Fassio F; Galli L; Lai A; Bergna A; Gabrieli A; Tarkowski M; Ventura CD; Colombo V; Cordier L; Bernasconi D; Corbellino M; Dedivitiis G; Borghetti S; Visigalli D; Sollima S; Casalini G; Rizzardini G; Gori A; Antinori S; Riva A; Schiavini M
Virol J; 2024 Mar; 21(1):68. PubMed ID: 38509536
[TBL] [Abstract][Full Text] [Related]
36. Characteristics and Outcomes of US Veterans With Immunocompromised Conditions at High Risk of SARS-CoV-2 Infection With or Without Receipt of Oral Antiviral Agents.
Gentry CA; Nguyen PN; Thind SK; Kurdgelashvili G; Williams RJ
Clin Infect Dis; 2024 Feb; 78(2):330-337. PubMed ID: 37619991
[TBL] [Abstract][Full Text] [Related]
37. Clinical characteristics of COVID-19 rebound after nirmatrelvir-ritonavir or molnupiravir therapy: A prospective cohort study.
Han J; Bae S; Jung J; Kim MJ; Chong YP; Lee SO; Choi SH; Kim YS; Chang E; Kim SH
Medicine (Baltimore); 2023 Sep; 102(39):e35094. PubMed ID: 37773854
[TBL] [Abstract][Full Text] [Related]
38. Non-randomized evaluation of hospitalization after a prescription for nirmatrelvir/ritonavir versus molnupiravir in high-risk COVID-19 outpatients.
Cowman K; Miller A; Guo Y; Chang MH; McSweeney T; Bao H; Simpson R; Braithwaite C; Sunu E; Ros T; Rodriguez M; Laboy E; Bard L; Alsina L; Cintron A; Andrews E; Nori P
J Antimicrob Chemother; 2023 Jul; 78(7):1683-1688. PubMed ID: 37229547
[TBL] [Abstract][Full Text] [Related]
39. Effectiveness of COVID-19 treatment with nirmatrelvir-ritonavir or molnupiravir among U.S. Veterans: target trial emulation studies with one-month and six-month outcomes.
Bajema KL; Berry K; Streja E; Rajeevan N; Li Y; Yan L; Cunningham F; Hynes DM; Rowneki M; Bohnert A; Boyko EJ; Iwashyna TJ; Maciejewski ML; Osborne TF; Viglianti EM; Aslan M; Huang GD; Ioannou GN
medRxiv; 2022 Dec; ():. PubMed ID: 36561190
[TBL] [Abstract][Full Text] [Related]
40. Comparative efficacy and safety of nirmatrelvir/ritonavir and molnupiravir for COVID-19: A systematic review and meta-analysis.
Amani B; Akbarzadeh A; Amani B; Shabestan R; Khorramnia S; Navidi Z; Rajabkhah K; Kardanmoghadam V
J Med Virol; 2023 Jun; 95(6):e28889. PubMed ID: 37368841
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
